Tradestie Institutional Equity Comparison Engine

ELVN vs VOR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ELVN Overall Edge

ELVN Captures Institutional Edge (3โ€“1 Pillars ยท 4โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Enliven Therapeutics, Inc. Common Stock (ELVN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while VOR counters with relative strength in Valuation. Fundamentally, ELVN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus VOR at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ELVN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against VOR sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner VOR
ELVN N/M vs VOR N/M Fwd P/E
Growth & Margin Winner ELVN
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner ELVN
1Y +135.5% vs +97.5% ยท 52W Pos 69% vs 65%
Options & Structure Winner ELVN
CONSOLIDATION (5th %ile IV) vs CONSOLIDATION (6th %ile IV)
ELVN NASDAQ
Enliven Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$47.73
-2.18% 1D
Market Cap $3.6B
1M Return +27.91%
1Y Return +135.5%
Forward P/E N/M
Unified AI Score
36.2 / 100 SELL
Tech 15.0 Fund 44.0 Flow 68.0 Mom 60.0
VOR NASDAQ
Vor Biopharma Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$19.26
-0.82% 1D
Market Cap $1.2B
1M Return +6.82%
1Y Return +97.54%
Forward P/E N/M
Unified AI Score
57.8 / 100 HOLD
Tech 50.0 Fund 55.0 Flow 66.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ELVN +135.5% VOR +97.54% Spread: +37.96 pp (ELVN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ELVN TTM Op. Margin: 0.0% VOR TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ELVN vs VOR. Trailing 12-month operating profitability (ELVN 0.0% vs VOR 0.0%) and valuation multiples (ELVN N/M vs VOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ELVN (4) vs VOR (2)
Institutional Metric ELVN VOR Criterion Row Winner
Market Capitalization Scale $3.6B $1.2B Larger Scale ELVN
Trailing P/E Ratio Valuation N/M 0.1x Lower Multiple VOR
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -16.8% -125.4% Higher ROE ELVN
52-Week Range Position Momentum 69% ($15โ€“$62) 65% ($6โ€“$26) Stronger Trend ELVN
Beta / 30D Volatility Risk Regime 0.96ฮฒ ยท 60% Vol 1.91ฮฒ ยท 61% Vol Lower Realized Risk ELVN
Unified Institutional Score Composite Signal 36.2 / 100 (SELL) 57.8 / 100 (HOLD) Higher Composite VOR

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ELVN vs VOR Buy Guide
ELVN CONSOLIDATION
59d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live ELVN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
VOR CONSOLIDATION
52d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live VOR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ELVN nor VOR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.